通过5'UTR-依赖的ADAM10翻译启动,SHMT2调解小分子诱导的阿尔茨海默病理的缓解
Li Song1, Qiu-Ling Pan1, Gui-Feng Zhou1
1Department of Neurology, Chongqing Key Laboratory of Major Neurological and Mental Disorders, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 6, 2024
概括
这项研究揭示了肯帕隆通过将单碳代谢 (OCM) 与RNA处理联系起来来增强阿尔茨海默病 (AD) 治疗. 代谢酶SHMT2作为RNA结合蛋白,促进ADAM10转化以改善AD小鼠的认知能力.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 化学生物学 化学生物学
背景情况:
- 一碳代谢 (OCM) 与阿尔茨海默病 (AD) 有关,但潜在的机制尚不清楚.
- 亚当金属化酶域10 (ADAM10) 是AD的潜在治疗标.
研究的目的:
- 为了调查OCM和AD病原体之间的联系.
- 在AD模型中探索kenpaullone (KEN) 的治疗潜力.
主要方法:
- 利用化学生物学方法来识别分子标.
- 研究了线粒体血清基甲基转移酶2 (SHMT2) 在调节ADAM10转化中的作用.
- 评估了KEN对APP/PS1小鼠认知功能的影响.
主要成果:
- 发现SHMT2可以直接调节ADAM10的翻译.
- 肯帕隆 (KEN) 通过其5'未翻译区域 (5'UTR) 促进了ADAM10的翻译,改善了AD小鼠的认知功能.
- SHMT2作为一个5'UTR相互作用的RNA结合蛋白 (RBP),通过GAGGG动机增强ADAM10的翻译启动,从而影响真核细胞启动因子2 (eIF2) 核糖体扫描.
结论:
- 肯帕隆通过将OCM与RNA处理连接起来,显示出对AD的治疗潜力.
- 代谢酶SHMT2作为RBP功能,促进5'UTR-依赖的ADAM10翻译启动,并为AD提供了一种新的治疗策略.
相关概念视频
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491